Importantly, MCM10 is shown to be served as a promising prognostic biomarker and MCM10 inhibitors Suramin, and its analogues are revealed to present potential anti‐cancer effects for ESCC. Here, MCM10 is linked to esophageal squamous cell carcinoma.